Background Direct oral anticoagulants (DOACs) have emerged as promising alternatives to
vitamin K antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or …

Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …

Direct oral anticoagulants have been an increasingly used class of drugs in the setting of
nonvalvular atrial fibrillation, defying vitamin K antagonists' monopoly when it comes to …

Aims The well-known limitations of vitamin K antagonists (VKA) led to development of new
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …

For most patients, direct oral anticoagulants (DOACs) are preferred over vitamin K
antagonists for stroke prevention in atrial fibrillation and for venous thromboembolism …

It is well established that direct oral anticoagulants (DOACs) are the cornerstone of
anticoagulant strategy in atrial fibrillation (AF) and venous thromboembolism (VTE) and …

The present study aimed to assess the associations between dosing of DOACs and
outcomes in patients with non-valvular atrial fibrillation (NVAF). Direct oral anticoagulants …

Background: In randomized controlled trials (RCTs) direct acting oral anticoagulants
(DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists …

Importance Dose-reduced regimens of direct oral anticoagulants (DOACs) may be used for
2 main purposes: dose-adjusted treatment intended as full-intensity anticoagulation (eg, for …